Our Leadership

Mr. Michas is the founder and has been Managing Partner of Juniper Investment Company, LLC since 2008. Juniper is also a Principal of Aetolian Investors, LLC, a registered commodity pool operator. Mr. Michas received a Bachelor of Arts degree from Harvard College and a Master of Business Administration degree from Harvard Business School. Mr. Michas is the Non-Executive Chairman of the board of BorgWarner Inc., a director of funds managed by Atlantic Investment Management, Inc., a board member of publicly traded AstroNova, Inc., as well as privately held Theragenics Corporation. Mr. Michas also served as the Non-Executive Chairman of the board of Lincoln Educational Services Corporation until 2015, and as a director of Allied Motion Technologies, Inc. until July 2017. Mr. Michas is the Chairman of the U.S. Board of Trustees of Athens College, a non-profit organization.

Mr. Michas was named Non-Executive Chairman of the board as of December 30, 2019. He brings to our board, and to the position of Non-Executive Chairman, many years of private equity experience across a wide range of industries, and a successful record of managing investments in public companies. Mr. Michas also brings extensive transactional expertise, including mergers and acquisitions, IPOs, debt and equity offerings, and bank financing. This expertise allows Mr. Michas to provide our board with valuable insight on trends in global debt and equity markets, and the impact of such trends on the capital structure of the Company. We also benefit from the corporate governance knowledge developed by Mr. Michas in his board roles with other public companies, including his service as a board chairman, a lead director, and a member of the compensation, governance, audit, finance and executive committees of such companies. Mr. Michas’ thorough knowledge of the Company and his current and past service on the boards of other public companies make him uniquely qualified to serve as our Non-Executive Chairman.

Mr. Barrett joined Atlas Venture, an early stage life sciences venture capital fund, in 2002 and is a partner in the life sciences group. Previously, he was a co-founder, Executive Vice President and Chief Business Officer of Celera Genomics. Prior to that, Mr. Barrett held several senior management positions at The Perkin-Elmer Corporation, most recently serving as Vice President, Corporate Planning and Business Development. He currently serves as the Chairman of Synlogic, Inc., and as a board member of Larimar Therapeutics and several privately held companies. Mr. Barrett is also a senior fellow at the Harvard Business School.

Mr. Barrett received his Bachelor of Science degree in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his Doctoral degree in analytical chemistry from Northeastern University.

Mr. Barrett brings to the board more than three decades of experience in the life sciences industry, including leadership positions both as a senior executive and as an institutional investor. These roles have allowed him to develop expertise in the deployment of strategic growth initiatives within the industry. His service as chair and as a member of the boards of other companies, both publicly and privately held, enables him to assist our board in the performance of its governance obligations.

Mr. Chapin was appointed Executive Vice Chairman of Global Corporate & Investment Banking at Bank of America Merrill Lynch in February 2010, where he was responsible for managing relationships with some of the firm's largest clients. Mr. Chapin retired from the firm as of June 30, 2016.

Mr. Chapin was named Vice Chairman of Merrill Lynch & Co in September 2003 and was a member of the firm's executive Operating Committee. From 2001 to 2003, he was Senior Vice President and Head of the Global Investment Banking division. Prior to that, he led the group within investment banking that covered industrial companies. He actively managed the firm's relationships with clients primarily in the industrial, resources and consumer products industries. Mr. Chapin has worked on a broad range of financings and strategic advisory assignments totaling more than $500 billion. Investment Dealers' Digest also named him Investment Banker of the Year.

Mr. Chapin joined Merrill Lynch in 1984 as a member of the Mergers & Acquisitions group and was named a managing director in Corporate Banking in 1993. He previously worked for Chase Manhattan Bank for three years in the corporate banking group. He is also a member of the board of directors of the Roundabout Theatre Company. He also serves on the board of trustees at Lafayette College and is a director for the Wharton Financial Advisory Board. Mr. Chapin is a member of the board of directors of CICOR International, Inc., a leading provider of flow control solutions and other highly engineered products for the industrial, energy and aerospace markets, O-I Glass, Inc., a world leader in glass bottle manufacturing, and PHINIA, a leader in the automotive components industry, all three of which are publicly-traded. Mr. Chapin was appointed a Senior Advisor to Rockefeller Capital Management, a leading independent, privately-owned financial services firm, in May 2019.

Mr. Chapin received a Bachelor of Arts from Lafayette College, where he was elected to the Phi Beta Kappa honor society. He also received a Master of Business Administration, with distinction, from The Wharton School at the University of Pennsylvania. Mr. Chapin brings to our board extensive knowledge of the industrial marketplace, along with deep experience in strategic advisory, mergers and acquisitions, and deal financing for a wide range of transactions.

Dr. Grégoire served as President of the Human Genetic Therapies division of Shire plc, a public biopharmaceutical company, from 2007 to 2013 and from 2005 to 2008 she served as a director of IDM Pharma, Inc., a public biotechnology company that now operates as a subsidiary of Takeda Pharmaceuticals, including serving as its Executive Chair from August 2006 to October 2007. From 2004 to 2005, Dr. Grégoire served as President, Chief Executive Officer and Executive Member of the board of directors of GlycoFi, Inc., a private biotechnology company. Prior to that, Dr. Grégoire was employed in several key operating and regulatory affairs positions at Biogen, Inc. (now known as Biogen Idec Inc.) and Merck & Co.

Dr. Grégoire currently serves on the board of Novo Nordisk and CervoMed. Dr. Grégoire holds a Bachelor of Science degree from Laval University and a Doctoral degree from the State University of New York at Buffalo.

Dr. Grégoire provides the board with a depth of experience in the management of commercial operations, manufacturing and regulatory affairs within the biotechnology industry, both domestically and internationally. Her extensive background gained over the course of almost thirty years of leadership positions with both public and private companies, as well as her current and past service on the boards of other public companies, will provide the board with valuable guidance in overseeing the strategic direction of the Company.

A medical doctor and molecular immunologist by training, Dr. Michelle McMurry-Heath most recently served as President and Chief Executive Officer of the Biotechnology Innovation Organization (BIO). She came to BIO from Johnson & Johnson where she served as Global Head of Evidence Generation for Medical Device Companies and then Vice President of Global External Innovation and Global Leader for Regulatory Sciences.

Prior to her time at J&J, Dr. McMurry-Heath was also a key science policy leader in government, conducting a comprehensive analysis of the National Science Foundation’s policies, programs and personnel. President Obama then named her associate science director of the FDA’s Center for Devices and Radiological Health.

Dr. McMurry-Heath was the founding director of the Aspen Institute’s Health, Biomedical Science, and Society Policy Program and received her early training in science policy from the Robert Wood Johnson Foundation.

Dr. McMurry-Heath also serves on the Board of Directors at Bioventus. She received her MD/PhD from Duke’s Medical Scientist Training Program, becoming the first African American to graduate from the prestigious program. She spent 12 years working at the research bench before taking policy and leadership roles in government and industry.

Dr. Singh was elected President and Chief Executive Officer of Revvity effective December 30, 2019, and appointed to our board of directors in August 2019. Previously Dr. Singh was the President and Chief Operating Officer of the Company since January 2019. Dr. Singh joined Revvity as the President of our Diagnostics business in May 2014. He was elected Senior Vice President in September 2016 and Executive Vice President in March 2018. Prior to joining Revvity, Dr. Singh was General Manager of GE Healthcare’s Women’s Health business from 2012 to 2014, with responsibility for its mammography and bone densitometry businesses. Before that, Dr. Singh held senior executive level roles in strategy, business development and mergers & acquisitions at both GE Healthcare and Philips Healthcare. Earlier in his career, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently Bristol-Myers Squibb Medical Imaging, which included managing the Asia Pacific and Middle East region.

Dr. Singh holds a doctoral degree in chemistry from the University of Missouri-Columbia and a Master of Business Administration from Northeastern University. His research work has resulted in several issued patents and publications in peer reviewed journals. He also currently serves on the Board of Directors of Amphenol Corporation and the Analytical, Life Science & Diagnostics Association (ALDA). Additionally, he is a member of the Massachusetts General Hospital President's Council. Dr. Singh has more than twenty-five years of leadership experience with global innovators in healthcare technology. He has spent the most recent eight years developing unique insights into both our business and our opportunities for continued growth. Dr. Singh brings to our board a detailed understanding of the core technologies that we utilize and the operational strategies available to us as we continue to focus on innovating for a healthier world.

Mr. Vounatsos is the former Chief Executive Officer of Biogen Inc., a publicly-traded company based in Cambridge, Massachusetts, having served in that position and been a member of Biogen’s board of directors from 2017 to 2022. Prior to joining Biogen in April 2016 as Executive Vice President, Chief Commercial Officer, Mr. Vounatsos spent twenty years at Merck & Co., Inc., a pharmaceutical company, where he most recently served as President, Primary Care, Customer Business Line and Merck Customer Centricity. In this role, Mr. Vounatsos led Merck’s global primary care business unit, encompassing Merck’s cardiology-metabolic, general medicine, women’s health and biosimilars groups and developed and instituted a strategic framework for enhancing the company’s relationships with key constituents, including the most significant providers, payers and retailers and the world’s largest governments. Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy, a pharmaceutical company. Mr. Vounatsos currently serves on the board of directors of Zai Lab limited, the advisory board of Tsinghua University School of Pharmaceutical Sciences, the Supervisory Board of Liryc, the Electrophysiology and Heart Modeling Institute at the University of Bordeaux, the board of directors of N-Lorem Foundation and as a member of the MIT Presidential CEO Advisory Board. Mr. Vounatsos received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.

Mr. Vounatsos joins our board with significant knowledge and broad-based experience with respect to the biotechnology, healthcare and pharmaceutical industries, a comprehensive global leadership background resulting from service as an executive in the pharmaceutical industry and his educational background in medicine and business. Mr. Vounatsos also brings valuable leadership skills gained as the chief executive officer of a publicly-traded multinational organization.

Dr. Witney most recently served as President and Chief Executive Officer of Affymetrix, Inc. (now part of Thermo Fisher Scientific), which specialized in microarray technology and cellular analysis. Previously, Dr. Witney was President and Chief Executive Officer of Dionex Corp., a market leading ion and high performance liquid chromatography company. Prior to that, Dr. Witney first joined Affymetrix when it acquired Panomics Inc., a quantitative biology company, which he led as President and Chief Executive Officer. He previously held the role of President of PerkinElmer’s Drug Discovery Tools division following the acquisition of Packard BioScience in 2001, where he served as President and Chief Operating Officer. Dr. Witney also held several positions at Bio-Rad Laboratories, leading that company's efforts to enter the proteomic and bioassay technologies market.

Dr. Witney is a member of the board of directors of publicly traded Cerus Corporation, Codex DNA and Standard BioTools, as well as several privately held companies, and is an Operating Partner at Ampersand Capital Partners.

Dr. Witney brings deep market knowledge and over 30 years of leadership experience across the life sciences, diagnostics and analytical instruments industry.

Ms. Witz brings more than two decades of global healthcare management experience to the Board. She most recently served as executive vice president, global diabetes and cardiovascular at Sanofi. During her tenure with the company, she launched multiple medicines across three continents and strengthened the pipeline through licensing and partnerships.

Prior to joining Sanofi, Ms. Witz served more than 17 years at GE Healthcare which included her final role as president and chief executive officer of its medical diagnostics business, a $2 billion integrated pharmaceutical organization that encompassed research and development through commercial.

Ms. Witz received her Master of Business Administration in Economics and Marketing from INSEAD and her Master of Science in Biochemistry from INSA Lyon. She currently serves on the board of directors for Horizon Pharma Plc, Regulus Therapeutics, Inc., and Fresenius Medical Care AG & Co. KGaA.